SLC5A2 and heart failure: All SGLT2 inhibitors have been shown to reduce the risk of worsening heart failure and subsequent hospitalization and death, with empagliflozin, dapagliflozin, and canagliflozin additionally demonstrating a reduction in the risk of major adverse cardiovascular events [11-15].